Year: 2003
Type: article
Abstract: Controversy in hematologyTransplantation for multiple myeloma: who, when, how often? High-dose therapy in multiple myeloma Joan Blade ´The outcome of patients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS).Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.
Source: Blood
Authors: Joan Bladé, David H. Vesole, Morie Gertz
Institutions: Hospital Clínic de Barcelona, Universitat de Barcelona
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2083814475